David A. Tuveson, MD, PhD, on Progress in Pancreatic Cancer: Expert Perspective
2017 ESMO CongressDavid A. Tuveson, MD, PhD, of Cold Spring Harbor Laboratory, discusses the most lethal of cancers. Although treatments are improving, the challenges are great, including early detection of this malignancy, which metastasizes early in its development.
Related Videos
Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update
Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.
Bernard J. Escudier, MD, on RCC: Results From the CheckMate 214 Trial
Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma,...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combinati...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...
Bonnie S. Glisson, MD, on HPV-16+ Cancer: Study Results
Bonnie S. Glisson, MD, of The University of Texas MD Anderson Cancer Center, discusses a clinical trial on the combination of ISA101, an HPV-16 vaccine, and nivolumab for patients ...
